Form 8-K · Current Report · Filed 2026-06-26
Dr. Randal W. Scott Resigns from BridgeBio Pharma Board
On June 22, 2026, Dr. Randal W. Scott resigned from the BridgeBio Pharma, Inc. Board of Directors upon the completion of his term as a Class I director. The Company's stockholders elected three new directors to the Board: James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D. Additionally, stockholders approved the compensation of named executive officers, approved a frequency of every 1 year for future non-binding advisory votes on executive compensation, ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm, and approved an amendment to the 2021 Stock Option and Incentive Plan.
- Filer
- BridgeBio Pharma Inc. BBIO · NASDAQ
- Filed
- Accession
- 0001140361-26-026506
- CIK
- 0001743881
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$69.69
Next session
+3.3%
Since filing
+14.9%
Latest close
$80.09
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from BBIO reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, BBIO insiders reported 90 Form 4 transactions — net selling of $31.2M.
About BridgeBio Pharma Inc.
BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
Never miss another BBIO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.